“…Overall, PASI75 was attained by 27-68% with short-term, 31-82% with intermediate-term and 44-89% with long-term (1 and 2 year) adalimumab treatment ( (Table SIII 1 ). Nine studies (13,18,20,22,24,26,32,33,35) were prospective and 11 retrospective (19, 21, 23, 25, 27-31, 34, 40), including a total of 2,079 patients. Five of 20 articles (21,25,29,31,40) reported results on etanercept monotherapy.…”